|
|
|
| Effect of Drug-eluting Beads Transcatheter Arterial Chemoembolization and Surgical Resection on Short-term and Long-term Efficacy of Stage Ⅱb Primary Liver Cancer |
| WANG Song, WANG Wen-chao, YANG Jun-chi, et al |
| Shanghai Yangpu District Central Hospital(Yangpu Hospital,Tongji University),Shanghai 200090 |
|
|
|
|
Abstract 【Objective】To compare the near-and long-term efficacy of drug-loaded microspheres through transcatheter hepatic arterial embolization (TACE) and surgical resection for stage Ⅱb primary liver cancer. 【Methods】A total of 68 patients with primary liver cancer of stage Ⅱb were random divided into groups A and B, with 34 cases each. The group B underwent surgical resection, while group A received CalliSpheres drug-eluting beads transarterial chemoembolization (DEB-TACE). Both groups received transarterial chemoembolization after relapse. The progression-free survival (DFS), overall survival (OS), blood biochemical data before and after treatment, complications, and short-term efficacy were compared between the two groups. 【Results】There were no significant differences in objective remission rate and the disease control rate at 1 month and at 3 months after treatment between the two groups (P>0.05). Compared with before treatment, the levels of VEGF, bFGF, AFP, TBIL, AST and ALT in both groups decreased after 3 months and after 6 months of treatment(P<0.05), while ALB increased after 3 months of treatment(P<0.05). There was no significant difference in the average cumulative number of TACE treatments between the two groups within 2 years after treatment (P>0.05). There was no significant difference in the incidence of complications between the two groups (P>0.05). There were no significant differences in cumulative DFS rate and cumulative OS rate between group A and group B (P>0.05). 【Conclusion】DEB-TACE is effective in the treatment of stage Ⅱb primary liver cancer, which is equivalent to the effect and prognosis of surgical resection, while DEB-TACE can reduce the number of TACE treatments and reduce the cost of hospitalization.
|
|
Received: 04 November 2020
|
|
|
|
|
|
[1] BUCKSTEIN M.Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma[J].J Gas Oncol,2018,9(4):734-740.
[2] ZHU D, YUAN D, WANG Z, et al. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients[J].Medicine (Baltimore),2019,98(26):e15682.
[3] 翟越,赵卫,潘文秋, 等.TACE联合载药微球治疗肝癌的研究进展[J].介入放射学杂志,2019,28(12):1211-1214.
[4] 中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗临床实践指南[J].中华放射学杂志,2019,53(4):246-255.
[5] 张余飞,康静波,温居一, 等.RECIST 1.1标准和mRECIST标准在原发性肝癌SBRT治疗后疗效评价中的对比研究[J].中国肿瘤临床,2016,43(20):902-906.
[6] ZOU J H,ZHANG L,REN Z G,et al. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis[J].J Dig Dis,2016, 17(8): 510-517.
[7] 曹国洪,王凯,李佳琪, 等.CalliSpheres(R)载药微球经动脉导管化疗栓塞治疗肝癌患者的有效性及安全性分析[J].中国介入影像与治疗学,2018,15(1):42-46.
[8] RAOUL J L.Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence[J].Cancer Treat Rev,2019,72:28-36.
[9] 陈猛.HepaSphere载药微球栓塞治疗原发性肝癌的近期疗效及安全性[J].肿瘤防治研究,2019,46(7):627-631.
[10] 段彬,罗成静,罗海阳.Callispheres可载药栓塞微球联合多西紫杉醇TACE对原发性肝癌患者bFGF VEGF和MVD的影响[J].河北医学,2019,25(1):14-18.
[11] 熊书名,郭飞宇,杨军, 等.AFP在肝癌术后患者生存预后中的价值[J].中华肝脏外科手术学电子杂志,2019,8(5):444-447. |
|
|
|
2021, Vol. 38 
